Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells

Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for... Prostate-specific antigen (PSA) is a widely used marker for the diagnosis and management of prostate cancer. Minimal enhancer/promoter constructs derived from the 5' flank of the human PSA gene (prostatespecific enhancer) were inserted into adenovirus type 5 DNA so as to drive the E1A gene, thereby creating a prostate-specific enhancer-containing virus, CN706. E1A was expressed at high levels in CN706-infected human PSA-producing LNCaP cells but not in CN706-infected DU145 cells, which are human prostate cells that do not express PSA. The titer of CN706 was significantly higher in LNCaP cells compared to several human cell lines that do not produce PSA (HBL100, PANC-1, MCF-7, DU145, and OVCAR3). Furthermore, in LNCaP cells, the yield of CN706 was dependent on exogenous androgen (R1881). CN706 destroyed large LNCaP tumors (1 x 10 9 cells) and abolished PSA production in nu/nu mouse xenograft models with a single intratumoral injection. 1 R. R., H. Y. L., and J. W. S. have no financial interest in Calydon, Inc., and were supported by NIH Specialized Programs of Research Excellence in Prostate Cancer Grant CA-58230 and the CapCure Foundation. 2 These authors made equal contributions to this work. 3 To whom requests for reprints should be addressed, at Calydon, Inc., 1014 Hamilton Court, Menlo Park, CA 94025. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells

Prostate Attenuated Replication Competent Adenovirus (ARCA) CN706: A Selective Cytotoxic for Prostate-specific Antigen-positive Prostate Cancer Cells

Cancer Research , Volume 57 (13): 2559 – Jul 1, 1997

Abstract

Prostate-specific antigen (PSA) is a widely used marker for the diagnosis and management of prostate cancer. Minimal enhancer/promoter constructs derived from the 5' flank of the human PSA gene (prostatespecific enhancer) were inserted into adenovirus type 5 DNA so as to drive the E1A gene, thereby creating a prostate-specific enhancer-containing virus, CN706. E1A was expressed at high levels in CN706-infected human PSA-producing LNCaP cells but not in CN706-infected DU145 cells, which are human prostate cells that do not express PSA. The titer of CN706 was significantly higher in LNCaP cells compared to several human cell lines that do not produce PSA (HBL100, PANC-1, MCF-7, DU145, and OVCAR3). Furthermore, in LNCaP cells, the yield of CN706 was dependent on exogenous androgen (R1881). CN706 destroyed large LNCaP tumors (1 x 10 9 cells) and abolished PSA production in nu/nu mouse xenograft models with a single intratumoral injection. 1 R. R., H. Y. L., and J. W. S. have no financial interest in Calydon, Inc., and were supported by NIH Specialized Programs of Research Excellence in Prostate Cancer Grant CA-58230 and the CapCure Foundation. 2 These authors made equal contributions to this work. 3 To whom requests for reprints should be addressed, at Calydon, Inc., 1014 Hamilton Court, Menlo Park, CA 94025.

Loading next page...
 
/lp/american-association-of-cancer-research/prostate-attenuated-replication-competent-adenovirus-arca-cn706-a-FGr3mF09X2

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 1997 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

Prostate-specific antigen (PSA) is a widely used marker for the diagnosis and management of prostate cancer. Minimal enhancer/promoter constructs derived from the 5' flank of the human PSA gene (prostatespecific enhancer) were inserted into adenovirus type 5 DNA so as to drive the E1A gene, thereby creating a prostate-specific enhancer-containing virus, CN706. E1A was expressed at high levels in CN706-infected human PSA-producing LNCaP cells but not in CN706-infected DU145 cells, which are human prostate cells that do not express PSA. The titer of CN706 was significantly higher in LNCaP cells compared to several human cell lines that do not produce PSA (HBL100, PANC-1, MCF-7, DU145, and OVCAR3). Furthermore, in LNCaP cells, the yield of CN706 was dependent on exogenous androgen (R1881). CN706 destroyed large LNCaP tumors (1 x 10 9 cells) and abolished PSA production in nu/nu mouse xenograft models with a single intratumoral injection. 1 R. R., H. Y. L., and J. W. S. have no financial interest in Calydon, Inc., and were supported by NIH Specialized Programs of Research Excellence in Prostate Cancer Grant CA-58230 and the CapCure Foundation. 2 These authors made equal contributions to this work. 3 To whom requests for reprints should be addressed, at Calydon, Inc., 1014 Hamilton Court, Menlo Park, CA 94025.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Jul 1, 1997

There are no references for this article.